HLA-DR and β2 microglobulin expression in medullary and atypical medullary carcinoma of the breast: Histopathologically similar but biologically distinct entities

Journal of Clinical Pathology

Volumn 53, Issue 4, 2000, Pages 286-291

  Feinmesser, Meora ^a   Sulkes, Aaron ^b   Morgenstern, Sara ^a   Sulkes, Jaqueline ^b   Stern, Sidi ^a   Okon, Elimelech ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b RABIN MEDICAL CENTER   (Israel)

Author keywords

2 microglobulin expression; HLA DR expression; Medullary carcinoma of the breast

Indexed keywords

BETA 2 MICROGLOBULIN; HLA DR ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ADULT; AGED; ANTIGEN PRESENTATION; ARTICLE; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNE SYSTEM; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; BETA 2-MICROGLOBULIN; BREAST NEOPLASMS; CARCINOMA, MEDULLARY; FEMALE; GENE EXPRESSION; GENES, MHC CLASS I; GENES, MHC CLASS II; HLA-DR ANTIGENS; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED;

EID: 0034124740     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.53.4.286     Document Type: Article

References (44)

1. 1 Doyle A, Martin JW, Funa K. Markedly decreased expression of class I histocompatibility antigens protein, and mRNA in human small cell lung cancer. J Exp Med 1985;161:1135-51.
2. 2 Holden CA, Sanderson AR, MacDonald DM. Absence of human leukocyte antigen molecules in skin tumors and some cutaneous appendages: evidence using monoclonal antibodies. J Am Acad Dermatol 1983;9:867-71.
3. 3 Lampson LA, Fisher CA, Whelan JP. Striking paucity of HLA-A, B, C and beta-2-microglobulin on human neuroblastoma cell lines. J Immunol 1983;130:2471-8.
4. 4 Hämmerling G, Maschek U, Sturmhöfel K, et al. Regulation and functional role of MHC expression on tumors. In: Melchers F, Albert ED, Von Boehmer AH, et al, eds. Progress in immunology, vol 7. Berlin: Springer-Verlag, 1989: 1071-8.
5. 5 Rubin JT, Elwood LJ, Rosenberg SA, et al. Immunohistochemical correlates of response to recombinant interleukin-2-based immunotherapy in humans. Cancer Res 1989;49: 7086-92.
6. 6 Vogel J, Tanaka K, Hoekzema GS, et al. Experimental strategies for modification of histocompatibility antigens in tumor cell. Cancer Metastasis Rev 1987;6:677-83.
7. 7 Goodenow RS, Vogel JM, Linsk RL. Histocompatibility antigens on murine tumors. Science 1985;230:777-83.
8. 8 Schrier PI, Bernards R, Vaessen RT, et al. Expression of class I major histocompatibility antigens switched off by highly oncogenic adenovirus 12 in transformed rat cells. Nature 1983;305:771-5.
9. 9 Kaufman JF, Auffray C, Korman AJ, et al. The class II molecules of the human and murine major histocompatibility complex. Cell 1984;36:1-13.
10. 10 Müller C, Ziegler A, Muller C, et al. Divergent expression of HLA-DC/MB, -DR and -SB region products on normal and pathological tissues as detected by monoclonal antibodies. Immunobiology 1985;169:228-49.
11. 11 Ghosh AK, Moore M, Street AJ, et al. Expression of HLA-D sub-region products on human colorectal carcinoma. Int J Cancer 1986;38:459-64.
12. 12 Hurlimann J, Saraga P. Mononuclear cells infiltrating human mammary carcinomas: Immunohistochemical analysis with monoclonal antibodies. Int J Cancer 1985;35: 753-62.
13. 13 Lucin K, Iternicka Z, Jonjic N. Prognostic significance of T-cell infiltrates, expression of β2-microglobulin and HLA-DR antigens in breast carcinoma. Pathol Res Pract 1994;190:1134-40.
14. 14 Weiss MA, Michael JG, Pesce AJ, et al. Heterogeneity of β2-microglobulin in human breast carcinoma. Lab Invest 1981;45:46-57.
15. 15 Zuk JA, Walker RA. Immunohistochemical analysis of HLA antigens and mononuclear infiltrates of benign and malignant breast. J Pathol 1987;152:275-85.
16. 16 Wintzer HO, Benzing M, von Kleist S. Lacking prognostic significance of B2-microglobulin, MHC class I and class II antigen expression in breast carcinomas. Br J Cancer 1990; 62:289-95.
17. 17 Concha A, Esteban F, Cabrera T, et al. Tumor aggressiveness and MHC class I and II antigens in laryngeal and breast cancer. Semin Cancer Biol 1991;2:47-54.
18. 18 Möller P, Mattfeldt T, Gross C, et al. Expression of HLA-A, -B, -C, -DR, -DP, -DQ, and of HLA-D-associated invariant chain (Ii) in non-neoplastic mammary epithelium, fibro-adenoma, adenoma, and carcinoma of the breast. Am J Pathol 1989;135:73-83.
19. 19 Pérez M, Cabrera T, Lopez Nevot MA, et al. Heterogeneity of the expression of class I and II HLA antigens in human breast carcinoma. J Immunogenet 1986;13:247-53.
20. 20 Concha A, Cabrera T, Ruiz-Cabello F, et al. Can the HLA phenotype be used as a prognostic factor in breast carcinomas? Int J Cancer 1991;6(suppl): 146-54.
21. 21 Tsuda H, Hirohashi S, Higuchi K, et al. Beta-2-microglobulin expression in relation to amplification of oncogenes and prognosis in breast carcinoma. Histopathology 1990;16:500-2.
22. 22 Natali PG, Giacomini P, Bigotti A, et al. Heterogeneity in the expression of HLA and tumor-associated antigens by surgically removed and cultured breast carcinoma cells. Cancer Res 1983;43:660-8.
23. 23 Bartek J, Petrek M, Vogtesek B, et al. HLA-DR antigens on differentiating human mammary gland epithelium and breast tumors. Br J Cancer 1987;56:727-33.
24. 24 Zuk JA, Walker RA. HLA class II sublocus expression in benign and malignant breast epithelium. J Pathol 1988;155: 301-9.
25. 25 Koretz K, Moldenhauer G, Majdic O, et al. Correlation of HLA-D/Ti antigen expression in breast carcinoma with local lymphohistiocytic infiltration reveals considerable dysregulation in a subset of tumors. Int J Cancer 1989;44:816-22.
26. 26 Brunner CA, Gokel JM, Riethmüller G, et al. Expression of HLA-D subloci DR and DQ by breast carcinomas is correlated with distinct parameters of favourable prognosis. Eur J Cancer 1991;27:411-16.
27. 27 Bernard D, Maurizis JC, Rusé F, et al. Presence of HLA-D/DR antigens on the membrane of breast tumor cells. Clin Exp Immunol 1984,56:215-21.
28. 28 Ridolfi RL, Rosen PP, Port A, et al. Medullary carcinoma of the breast: a clinicopathologic study with 10-year follow-up. Cancer 1977;40:1365-85.
29. 29 Tavassoli FA. Pathology of the breast. Norwalk, Connecticut: Appleton and Lange, 1992:333-9.
30. 30 Yazawa T, Kamma H, Ogata T. Frequent expression of HLA-DR antigen in medullary carcinoma of the breast. A possible reason for its prominent lymphocytic infiltration and favorable prognosis. Appl Immunohistochem 1993;1: 289-96.
31. 31 Wargotz ES, Silverberg SG. Medullary carcinoma of the breast: a clinicopathologic study with appraisal of current diagnostic criteria. Hum Pathol 1988;19:1340-6.
32. 32 Beahrs OH, Henson DE, Hutter RVP, et al. Handbook for staging of cancer, from the manual for staging of cancer, 4th ed. American Joint Committee on Cancer, TNM Committee of the International Union Against Cancer. Philadelphia: JB Lippincott Co, 1993:165-7.
33. 33 Taylor CR. Immunoperoxidose techniques. Arch Pathol Lab Med 1978;102:113-21.
34. 34 Mephan BL, Frater W, Mitchell BS. The use of proteolytic enzymes to improve immunoglobulin staining by the PAP technique. Histochem J 1979;11:345-7.
35. 35 Rapin V, Contesso G, Mouriesse H, et al. Medullary breast carcinoma: a reevaluation of 95 cases of breast cancer with inflammatory stroma. Cancer 1988;61:2503-10.
36. 36 Benezra J, Sheibani K. Antigenic phenotype of the lymphocytic component of medullary carcinoma of the breast. Cancer 1987;59:2037-41.
37. 37 Rubens JR, Lewandrowski KB, Kopans DB, et al. Medullary carcinoma of the breast. Over-diagnosis of a prognostically favorable neoplasm. Arch Surg 1990;125:601-4.
38. 38 Balch CM, Riley LB, Bae YJ, et al. Patterns of human tumor-infiltrating lymphocytes in 120 human cancers. Arch Surg 1990;125:200-5.
39. 39 Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992;339:71-85.
40. 40 Cohen PJ, Lotze MT, Roberts JR, et al. The immunopathology of sequential tumor biopsies in patients treated with interleukin-2. Correlation of response with T-cell infiltration and HLA-DR expression. Am J Pathol 1987;129:208-16.
41. 41 Tanaka K, Isselbacher KJ, Khoury G, et al. Reversal of oncogenesis by the expression of a major histocompatibility complex class I gene. Science 1985;228:26-30.
42. 42 Matory YL, Chen M, Dorfman DM, et al. Antitumor activity of three mouse mammary cancer cell lines after interferon-gamma gene transfection. Surgery 1995;118: 251-6.
43. 43 Jabran-Ferrat N, Faille A, Loiscau P, et al. Effect of gamma Interferon on class I and II transcription and protein expression in human breast adenocarcinoma cell lines. Int J Cancer 1990;45:1169-76.
44. 44 Bernard DJ, Courjal F, Maurizis JC, et al. Effect of epidermal growth factor in HLA class I and class II transcription and protein expression in human breast adenocarcinoma cell lines. Br J Cancer 1992;66:88-92.